The design and synthesis of novel structural platforms which can project substituents into multiple regions of the receptor space is an important goal in the search for new leads for the discovery of molecular probes and eventually drugs. The proposed research intends to investigate the versatility of organometallic and inorganic compounds as structural scaffolds for the design of specific enzyme inhibitors. Such metal-ligand assemblies will allow convergent and economical synthetic approaches and will give access to structural motifs that differ from purely organic molecules. The specific goal of this research program encompasses the development of inert metal complexes that target the ATP-binding site of protein kinases. ATP-competitive inhibitors generally reach into the adenine binding pocket and form hydrogen bonds with the peptide backbone. Metal complexes with one ligand that bears the main structural features of one of these scaffolds can copy their mode of action. Additional ligands in the coordination sphere of the metal are intended to undergo specific contacts with other parts of the active site. Main focus will be the transformation of the class of indolocarbazole and indirubin inhibitors into metal complex scaffolds. This project includes the design and synthesis of adenine pocket-binding chelate ligands, the synthesis and examination of metal complexes, rational inhibitor design by molecular modeling, x-ray crystallographic studies of protein kinase domains in complex with metal compounds, structure-activity relationships, and combinatorial chemistry with metal complexes. The project bridges the fields of organic and inorganic medicinal chemistry by using metal centers as chemically inert structural scaffolds for drug design. This novel approach might lead to a new class of therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM071695-05
Application #
7648236
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Fabian, Miles
Project Start
2005-05-01
Project End
2010-04-30
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
5
Fiscal Year
2009
Total Cost
$211,106
Indirect Cost
Name
University of Pennsylvania
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Desai, Brijal M; Villanueva, Jessie; Nguyen, Thierry-Thien K et al. (2013) The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 8:e59588
Feng, Li; Geisselbrecht, Yann; Blanck, Sebastian et al. (2011) Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc 133:5976-86
Pinnix, Chelsea C; Lee, John T; Liu, Zhao-Jun et al. (2009) Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 69:5312-20
Xie, Xiulan; Mulcahy, Seann P; Meggers, Eric (2009) Strategy for the stereochemical assignment of tris-heteroleptic Ru(II) complexes by NMR spectroscopy. Inorg Chem 48:1053-61
Anand, Ruchi; Maksimoska, Jasna; Pagano, Nicholas et al. (2009) Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. J Med Chem 52:1602-11
Pagano, Nicholas; Wong, Eric Y; Breiding, Tom et al. (2009) From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors. J Org Chem 74:8997-9009
Meggers, Eric (2009) Targeting proteins with metal complexes. Chem Commun (Camb) :1001-10
Maksimoska, Jasna; Williams, Douglas S; Atilla-Gokcumen, G Ekin et al. (2008) Similar biological activities of two isostructural ruthenium and osmium complexes. Chemistry 14:4816-22
Smalley, Keiran S M; Contractor, Rooha; Nguyen, Thiennga K et al. (2008) Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 68:5743-52
Maksimoska, Jasna; Feng, Li; Harms, Klaus et al. (2008) Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 130:15764-5

Showing the most recent 10 out of 26 publications